AXIS Capital Holdings Limited, through its subsidiaries, provides various specialty insurance and reinsurance products in Bermuda, the United States, and internationally. It operates through two segments, Insurance and Reinsurance. The Insurance segment offers professional insurance products that cover directors' and officers' liability, errors and omissions, employment practices, fiduciary, crime, professional indemnity, medical malpractice, and other financial insurance related coverages for commercial enterprises, financial institutions, not-for-profit organizations, and other professional service providers; and property insurance products for commercial buildings, residential premises, construction projects, property in transit, onshore renewable energy installations, and physical damage and business interruption following an act of terrorism. This segment also provides marine and aviation insurance services for offshore energy, offshore renewable energy, cargo, liability, including kidnap and ransom, fine art, specie, and hull war, hull and liability, and specific war coverage for passenger airlines, cargo operations, general aviation operations, airports, aviation authorities, security firms, and  product manufacturers; personal accident, travel insurance, specialty health products for employer and affinity groups, and pet insurance products; and liability, cyber, and credit and political risk insurance services. The Reinsurance segment offers agriculture, marine and aviation, catastrophe, accidental and health, credit and surety, motor, professional, travel, life, engineering, property, and liability reinsurance products. AXIS Capital Holdings Limited was founded in 2001 and is headquartered in Pembroke, Bermuda.

Axis Capital Holdings Limited

In a report released today, Leonid Timashev from RBC Capital maintained a Buy rating on Axsome Therapeutics, with a price target of $198.00. Timash...

RBC Capital Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Axsome Therapeutics today and set a price target of $202.00. According to Ti...

Mizuho Securities Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

In a report released today, from Panmure Liberum reiterated a Buy rating on Accsys Technologies, with a price target of p100.00. The word on The St...

Panmure Liberum Remains a Buy on Accsys Technologies (AXS)

KBW analyst Meyer Shields maintained a Buy rating on Axis Capital yesterday and set a price target of $121.00. According to TipRanks, Shields is a ...

KBW Remains a Buy on Axis Capital (AXS)

Axis Capital ( ($AXS) ) has provided an announcement. On November 19, 2025, AXIS Capital Holdings Limited entered into a stock repurchase agreement...

Current Quarter	$2.95	Next Quarter	$2.96
Current Year	$12.66	Next Year	$12.62
QoQ Growth	+0.3%	YoY Growth	-0.3%
3Y EPS CAGR	N/A	Target Price	$115.60
Consensus	Buy	Upside	+10.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AXS	$104.36	+0.70%	455.13K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AXS	$104.36	+0.7%	455.13K
3
4
5
6

AXS

AXS

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Axis Capital Holdings Limited Data in Excel

Get Axis Capital Holdings Limited Data in Excel